Advancing Medicines for a Brighter Future
Developing a pipeline of products aimed at primary and metastatic cancers of the brain
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma, medulloblastoma and paediatric diffuse midline glioma.
MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.
Glioblastoma is the most common and devastating primary malignant brain tumour in adults
Our lead candidate, MTX110, is being studied in multiple serious and aggressive brain cancer indications including recurrent glioblastoma and diffuse midline glioma.
Biodexa Pharmaceuticals PLC is listed on NASDAQ: BDRX. Visit our investor resources for shareholder information and latest news and reports.